People · Operator
Named in public records as an officer, director or promoter · active 2021–2025 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Coeptis Therapeutics Holdings, Inc. | — | Pharmaceuticals | Series A | $10.3M | $12.8M | 2024 |
| Coeptis Therapeutics Inc. | — | Pharmaceuticals | Series A | $5.5M | $125.1M | 2021 |
Daniel Yerace at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Daniel Yerace on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Mehalick | 2 | 5 |
| Christine Sheehy | 2 | 3 |
| Michael Handley | 1 | 4 |
| Colleen Delaney | 1 | 4 |
| Brian Cogley | 1 | 3 |
| Tara Maria DeSilva | 1 | 1 |
| Gene Maria Salkind | 1 | 1 |
| Christopher Calise | 1 | 1 |
| Christopher Maria Cochran | 1 | 1 |
| Christopher Cochran | 1 | 1 |
| Philippe Maria Deschamps | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.